

DAFTAR PUSTAKA

- ABADÍAS-GRANADO, I., SÁNCHEZ-BERNAL, J. & GILABERTE, Y. 2021. The microbiome and aging. *Plastic and Aesthetic Research*, 8.
- ALEXEYEV, O. A., DEKIO, I., LAYTON, A., LI, H., HUGHES, H., MORRIS, T., ZOUBOULIS, C. & PATRICK, S. 2018. Why we continue to use the name Propionibacterium acnes. *The British journal of dermatology*, 179, 1227-1227.
- AMON, P. & SANDERSON, I. 2017. What is the microbiome? *Archives of Disease in Childhood-Education and Practice*, 102, 257-260.
- ANGGRAENI, Reti; ROSITA, Fiska; KUSUMAWARDANI, Arie. Terapi Probiotik (Lactococcus lactis) Topikal untuk Akne Vulgaris: Kasus Serial. *Cermin Dunia Kedokteran*, 2021, 48.1: 33-38.
- Ayudianti P, Indramaya DM. 2014. Studi Retrospektif: Faktor Pencetus Akne Vulgaris. Ilmu Kesehatan Kulit & Kelamin Berkala. 26(1): 41-47.
- Baumann L and Allemann IB. Acne. In Baumann L, Saghari S., 2010 Weisberg E (eds) Cosmetic Dermatology, Principles and Practice. 2nd ed. New York. Mc Graw Hill Medical. 121-27.
- CAROLYN GOH, C. C., GEORGE AGAK, , ANDREA L. ZAENGLEIN, E. M. G. & DIANE M. THIBOUTOT, J. K. 2019. Acne Vulgaris. In: SEWON KANG, M. A., ANNA L. BRUCKNER,ALEXANDER H. ENK, DAVID J. MARGOLIS, AMY J. MCMICHAEL, JEFFREY S. ORRINGER. (ed.) *Fitzpatrick Dermatology*. 9th ed. New York: Mc Graw Hill.
- Dagnelie, Marie-Ange, et al. "Inflammatory skin is associated with changes

- in the skin microbiota composition on the back of severe acne patients." *Experimental dermatology* 28.8 (2019): 961-967.
- DRÉNO, B. What is new in the pathophysiology of acne, an overview. *Journal of the European Academy of Dermatology and Venereology*, 2017, 31: 8-12.
- Everts HB. 2012. Endogenous Retinoids in The Hair Follicle and Sebaceous Gland. *Biochimica et Biophysica Acta*. 1821: 222-29.
- EYERICH, S., EYERICH, K., TRAIDL-HOFFMANN, C. & BIEDERMANN, T. 2018. Cutaneous barriers and skin immunity: differentiating a connected network. *Trends in immunology*, 39, 315-327.
- FRANÇA, Katlein. Topical probiotics in dermatological therapy and skincare: a concise review. *Dermatology and therapy*, 2021, 11: 71-77.
- GOBBETTI, M. 2000. Lactobacillus casei.
- Goh C, Cheng C, Agak G, Zaenglein A, Gruber EM, Thiboutot DM & Kim J. 2019. Acne vulgaris. In: Kang S, Amagai M, Bruckner AL, Enk AH, Morgolis DJ, McMichael AJ, et al. Eds. *Fitzpatrick's dermatology*. 9th edition. New York, McGraw-Hill. p. 1391-418.
- GOODARZI, A., MOZAFARPOOR, S., BODAGHABADI, M. & MOHAMADI, M. 2020. The potential of probiotics for treating acne vulgaris: A review of literature on acne and microbiota. *Dermatologic therapy*, 33, e13279.
- Goodarzi, Azadeh, et al. "The potential of probiotics for treating acne vulgaris: A review of literature on acne and

microbiota." *Dermatologic therapy* 33.3 (2020): e13279.Picardo M, Eichenfield LF, Tan J. 2017. Acne and Rosacea. *Dermatol Ther* (Heidelb). 7(1): S43-S52.

HABEEBUDDIN, Mohammed, et al. Topical probiotics: More than a skin deep. *Pharmaceutics*, 2022, 14.3: 557.

HOSSEINI, S., VÁZQUEZ-VILLEGAS, P., RITO-PALOMARES, M. & MARTINEZ-CHAPA, S. O. 2018. General overviews on applications of ELISA. *Enzyme-linked Immunosorbent Assay (ELISA)*. Springer.

Hosseini S, et al. 2018. Enzyme-Linked Immunosorbent Assay (ELISA). *Forensic and Bioinformatics*. Springer. 5: 67-115.

Jusuf, Nelva Karmila, Imam Budi Putra, and Lovena Sari. "Differences of microbiomes found in non-inflammatory and inflammatory lesions of acne vulgaris." *Clinical, Cosmetic and Investigational Dermatology* 13 (2020): 773.Vahlquist A. 1982. Vitamin A in Human Skin: I. Detection and Identification of Retinoids in Normal Epidermis. *J Investigative Dermatol*. 79: 89-93.

Karadag, A. S., et al. "Antibiotic resistance in acne: changes, consequences and concerns." *Journal of the European Academy of Dermatology and Venereology* 35.1 (2021): 73-78.Zaenglein AL, et al. 2016. Guidelines of Care for The Management of Acne Vulgaris. *J Am Acad Dermatol*. 74(5): 945-73.

KIM, Mi-Ju, et al. Mixed starter of Lactococcus lactis and Leuconostoc citreum for extending kimchi shelf-life. *Journal of Microbiology*, 2019, 57.6: 479-484.

Kistowska, Magdalena, et al. "Propionibacterium acnes promotes Th17 and Th17/Th1 responses in acne patients." *Journal of Investigative Dermatology* 135.1 (2015): 110-118.

KLAENHAMMER, Todd R. Genetics of bacteriocins produced by lactic acid bacteria. *FEMS microbiology reviews*, 1993, 12.1-3: 39-85.

KONSTANTINOU, G. N. 2017. Enzyme-linked immunosorbent assay (ELISA). *Food Allergens*. Springer.

LEE, Se Hee, et al. Unraveling microbial fermentation features in kimchi: from classical to meta-omics approaches. *Applied Microbiology and Biotechnology*, 2020, 104: 7731-7744.

LEE, Y. B., BYUN, E. J. & KIM, H. S. 2019. Potential role of the microbiome in acne: a comprehensive review. *Journal of clinical medicine*, 8, 987.

Lee, Young Bok, Eun Jung Byun, and Hei Sung Kim. "Potential role of the microbiome in acne: a comprehensive review." *Journal of clinical medicine* 8.7 (2019): 987. Schmidt CK, Brouwer A, Nau H. 2003. Chromatographic Analysis of Endogenous Retinoids in Tissues and Serum. *J Analytical Biochemistry*. 315: 36-48.

Lehmann HP, et al. 2002. Acne therapy : a methodological review. *J Am Acad Dermatol*. 47(2): 231-40.

LEHMANN, H. P., ROBINSON, K. A., ANDREWS, J. S., HOLLOWAY, V. & GOODMAN, S. N. 2002. Acne therapy: a methodologic review. *Journal of the American Academy of Dermatology*, 47, 231-240.

MATEJUK, A. 2018. Skin immunity. *Archivum immunologiae et therapiae*

- experimentalis*, 66, 45-54.
- MARSON, Justin W.; BALDWIN, Hilary E. An overview of acne therapy, part 1: topical therapy, oral antibiotics, laser and light therapy, and dietary interventions. *Dermatologic clinics*, 2019, 37.2: 183-193.
- MOON, Y. 2016. Microbiome-linked crosstalk in the gastrointestinal exposome towards host health and disease. *Pediatric gastroenterology, hepatology & nutrition*, 19, 221-228.
- OH, Sejong, et al. Effect of bacteriocin produced by Lactococcus sp. HY 449 on skin-inflammatory bacteria. *Food and chemical toxicology*, 2006, 44.4: 552-559.
- O'NEILL, A. M. & GALLO, R. L. 2018. Host-microbiome interactions and recent progress into understanding the biology of acne vulgaris. *Microbiome*, 6, 1-16.
- O'Neill, Alan M., and Richard L. Gallo. "Host-microbiome interactions and recent progress into understanding the biology of acne vulgaris." *Microbiome* 6.1 (2018): 1-16. Bhate K, Williams HC. 2013. Epidemiology of Acne Vulgaris. *British J Dermatol.* 168: 474-85.
- OZCELIK, S., KULAC, I., YAZICI, M. & OCAL, E. 2018. Distribution of childhood skin diseases according to age and gender, a single institution experience. *Turkish Pediatrics Archive*, 53, 105-113.
- PANDE, S. & MISRI, R. 2005. Sebumeter. *Indian Journal of Dermatology, Venereology, and Leprology*, 71.
- Petkova V, et al. 2018. Impact of Acne on Patients' Quality of Life in Bulgaria. *J Endocrinol Thyroid Res.* 3(3): 001-004.

PICARDO, Mauro; EICHENFIELD, Lawrence F.; TAN, Jerry. Acne and rosacea. *Dermatology and therapy*, 2017, 7: 43-52.

Plewig et al., 2019. Plewig and Kligman's Acne and Rosacea. Springer Nature Switzerland AG. 7(1): 217-22.

ROCHA, M. & BAGATIN, E. 2018. Skin barrier and microbiome in acne. *Archives of dermatological research*, 310, 181-185.

Rocha, M. A., and Edileia Bagatin. "Skin barrier and microbiome in acne." *Archives of dermatological research* 310.3 (2018): 181-185.

Cong TX, et al. 2019. From Pathogenesis of Acne Vulgaris to Anti-Acne Agents. *Archives Dermatol Research*. 1-13.

RYBAK, Iryna, et al. Prospective Placebo-Controlled Assessment of Spore-Based Probiotic Supplementation on Sebum Production, Skin Barrier Function, and Acne. *Journal of Clinical Medicine*, 2023, 12.3: 895.

SÁNCHEZ-PELLICER, Pedro, et al. Acne, Microbiome, and Probiotics: The Gut–Skin Axis. *Microorganisms*, 2022, 10.7: 1303.

SERNA COCK, Liliana; RODRÍGUEZ DE STOUVENEL, Aida. Lactic acid production by a strain of *Lactococcus lactis* subs *lactis* isolated from sugar cane plants. *Electronic Journal of Biotechnology*, 2006, 9.1: 0-0.

SFRISO, Riccardo, et al. Revealing the secret life of skin-with the microbiome you never walk alone. *International journal of cosmetic science*, 2020, 42.2: 116-126.

SUDARMONO, P. P. 2016. Mikrobioma: Pemahaman baru tentang peran

- mikroorganisme dalam kehidupan manusia. *eJournal Kedokteran Indonesia*, 71-5.
- SUTARIA, A. H., MASOOD, S. & SCHLESSINGER, J. 2020. Acne vulgaris. *StatPearls [Internet]*.
- SUVANPRAKORN, P., TONGYEN, T., PRAKHONGCHEEP, O., LAORATTHAPHONG, P. & CHANVORACHOTE, P. 2019. Establishment of an Anti-acne Vulgaris Evaluation Method Based on TLR2 and TLR4-mediated Interleukin-8 Production. *in vivo*, 33, 1929-1934.
- SZEGEDI, A., DAJNOKI, Z., BÍRÓ, T., KEMÉNY, L. & TÖRÖCSIK, D. 2019. Acne: Transient Arrest in the Homeostatic Host–Microbiota Dialog? *Trends in immunology*, 40, 873-876.
- TSUJI, Ryohei, et al. The effects of dietary supplementation of *Lactococcus lactis* strain plasma on skin microbiome and skin conditions in healthy subjects—a randomized, double-blind, placebo-controlled trial. *Microorganisms*, 2021, 9.3: 563.DAS, Shinjita; REYNOLDS, Rachel V. Recent advances in acne pathogenesis: implications for therapy. *American journal of clinical dermatology*, 2014, 15: 479-488.
- WOLF, F., et al. A novel lantibiotic from *Lactococcus lactis* for the treatment of acne vulgaris. *Journal of Investigative Dermatology*, 1997, 4.108: 657.
- WOO, T. E. & SIBLEY, C. D. 2020. The emerging utility of the cutaneous microbiome in the treatment of acne and atopic dermatitis. *Journal*

- of the American Academy of Dermatology*, 82, 222-228.
- Wu, S., Bhat, Z. F., Gounder, R. S., Mohamed Ahmed, I. A., Al-Juhaimi, F. Y., Ding, Y., & Bekhit, A. E. D. (2022). Effect of dietary protein and processing on gut microbiota—a systematic review. *Nutrients*, 14(3), 453.
- XU, H. & LI, H. 2019. Acne, the skin microbiome, and antibiotic treatment. *American journal of clinical dermatology*, 20, 335-344.
- YOUN, S. W., KIM, S. J., HWANG, I. A. & PARK, K. C. 2002. Evaluation of facial skin type by sebum secretion: discrepancies between subjective descriptions and sebum secretion. *Skin Research and Technology*, 8, 168-172.
- Xu, Haoxiang, and Huiying Li. "Acne, the skin microbiome, and antibiotic treatment." *American journal of clinical dermatology* 20.3 (2019): 335-344.
- Rollman O, Vahlquist A. 1985. Vitamin A in Skin and Serum – Studies of Acne Vulgaris, Atopic Dermatitis, Ichthyosis Vulgaris and Lichen Planus. *British J Dermatol*. 113: 405-13.
- Zaenglein AL. 2018. Acne Vulgaris. *N Engl J Med*. 379: 1343-52.
- Zaenglein, A. L. and D. M. Thiboutot. 2017. Acne vulgaris. In: Jeffrey P C, Edward W C, George J H, Joseph L J, Harvey L, Luis R, et al. Eds. *Bolognia Textbook of Dermatology*. 4th Edition. USA, Elsevier. 36: 588-603.
- ZHANG, Bo, et al. Toll-like receptor 2 plays a critical role in pathogenesis of acne vulgaris. *Biomedical Dermatology*, 2019, 3.1: 1-6.

Lampiran 1. Persetujuan Etik





REKOMENDASI PERSETUJUAN ETIK

Nomor : 47/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 31 Januari 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22010004	No Sponsor Protokol	
Peneliti Utama	Prof. Dr. dr. Anis Irawan Anwar, Sp.KK(K), FINSDV, FAADV	Sponsor	
Judul Peneliti	EFEKTIVITAS MIKROBIOM TOPIKAL YANG MENGANDUNG LACTOBACILLUS PLANTARUM TERHADAP KADAR IL 8, IL 12, TNF ALPHA DAN ANTI INFLAMASI IL 10 SEBAGAI PENGOBATAN ACNE VULGARIS		
No Versi Protokol	2	Tanggal Versi	28 Januari 2022
No Versi PSP	2	Tanggal Versi	28 Januari 2022
Tempat Penelitian	RS Universitas Hasanuddin dan RS Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input checked="" type="checkbox"/> Fullboard Tanggal 18 Januari 2022	Masa Berlaku 31 Januari 2022 sampai 31 Januari 2023	Frekuensi review lanjutan
Ketua KEPK FKUH RSUH dan RSW	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	 Tanda tangan	
Sekretaris KEPK FKUH RSUH dan RSW	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	 Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui [protocol deviation / violation]
- Mematuhi semua peraturan yang ditentukan

Lampiran 2. Alat dan Bahan



Lampiran 3. Inform Consent

**SURAT PERNYATAAN PERSETUJUAN
UNTUK IKUT SERTA DALAM PENELITIAN
(INFORMED CONSENT)**

Yang bertanda tangan dibawah ini:

N a m a :

U s i a :

Alamat :

Pekerjaan :

No. KTP/lainnya:

Dengan ini menyatakan bahwa:

Telah memperoleh penjelasan sepenuhnya, menyadari, mengerti, dan memahami tentang tujuan, manfaat dan risiko yang mungkin timbul dalam penelitian yang berjudul:

"Efektivitas Mikrobiom Topikal yang Mengandung Lactococcus Ferment Lysate Terhadap IL 12, IL 8, TNF Alpha, IL 10, dan IL 1 sebagai Pengobatan Akne Vulgaris"

Maka dengan ini saya menyatakan :

setuju/tidak setuju*) berperan serta dalam penelitian ini

Demikian surat pernyataan ini kami buat dengan sesungguhnya dan tanpa paksaan.

Makassar, 2022

Peserta penelitian,

(.....)

Lampiran 4. Kuisioner Penelitian

Kode Penelitian:

KUISIONER PENELITIAN

Efektivitas Mikrobiom Topikal yang Mengandung Lactococcus Ferment Lysate

Terhadap IL 12, IL 8, TNF Alpha, IL 10 dan IL 1 sebagai Pengobatan Akne

Vulgaris

Nama : Berat Badan : Kg

Umur : Tahun Tinggi : Cm

Alamat:

No. Telpon :

ID LINE:

Pendidikan Terakhir : 1. SD 4. Akademi/Sarjana

2. SMP 5. Sekolah.....

3. SMA/Sederajat

Agama : 1. Islam 4. Budha

2. Kristen 5. Lainnya.....

3. Hindu

Pekerjaan : 1. Pelajar 4. Swasta

2. Mahasiswa 5. Lainnya.....

3. PNS

Aktivitas Rutin : 1. Luar Ruangan 2. Dalam Ruangan

Apakah mengalami stres dalam waktu : 1. Ya 2. Tidak

Kebiasaan memencet jerawat

Merokok : 1. Ya 2. Tidak

Alkohol : 1. Ya 2. Tidak

Kebiasaan Makan :

Kacang: 1. Setiap hari 2. Sekali Seminggu 3. Sekali sebulan 4.Tidak pernah

Coklat : 1. Setiap hari 2. Sekali Seminggu 3. Sekali sebulan 4.Tidak pernah

Makanan pedes: 1. Setiap hari 2. Sekali Seminggu 3. Sekali sebulan 4.Tidak pernah

Riwayat Jerawat : 1. <6bulan 2. > 6bulan

Pemakaian Kosmetik : 1. Ya 2. Tidak

Jika "Ya", Kosmetik yang digunakan:.....

Riwayat penggunaan obat untuk jerawat: 1. Ya 2. Tidak

Jika " Ya ", obat yang digunakan.....

Apakah sudah menikah : 1. Ya 2. Tidak

Tidur Teratur : 1. Ya 2. Tidak

Apakah menstruasi Anda teratur tiap bulan? : 1. Ya 2. Tidak

Kapan Terakhir Haid :

Berapa lama menstruasi Anda? :
1. <5hari
2. 5-7 hari
3. > 7hari

Berapa lama panjang siklus menstruasi Anda? (siklus menstruasi adalah rata-rata jumlah hari dari rentang hari pertama menstruasi awal sampai hari pertama menstruasi berikutnya, selama 3 bulan terakhir):
1. <24 hari
2. 24 - 30 hari
3. >30 hari

** Manifestasi Klinik

Komedo :

Papul :

Pustul :

Daerah wajah	Hari 0	Hari 14	Hari 28

NB: **Diisi oleh peneliti

Makassar,

2022

()

Lampiran 5. Data Sampel

Perbandingan Penggunaan Krim A dan B Sebelum (W0) dan Sesudah (W8)

Case Processing Summary



	Hasil	Cases					
		Valid		Missing		Total	
		N	Percent	N	Percent	N	Percent
Pre	A	35	100.0%	0	0.0%	35	100.0%
	B	35	100.0%	0	0.0%	35	100.0%
Post	A	35	100.0%	0	0.0%	35	100.0%
	B	35	100.0%	0	0.0%	35	100.0%

Descriptives

	Hasil			Statistic	Std. Error
Pre	A	Mean		253736.83	9778.303
		95% Confidence Interval for Mean	Lower Bound	233864.93	
			Upper Bound	273608.73	
		5% Trimmed Mean		249607.16	
		Median		240603.00	
		Variance		3346532022.087	
		Std. Deviation		57849.218	
		Minimum		172603	

		Maximum	432909	
		Range	260306	
		Interquartile Range	69098	
		Skewness	1.039	.398
		Kurtosis	1.502	.778
B		Mean	257184.09	9335.636
		95% Confidence Interval for Mean	Lower Bound Upper Bound	238211.79 276156.38
		5% Trimmed Mean		253656.30
		Median		246848.00
		Variance		3050393428.610
		Std. Deviation		55230.367
		Minimum		181367
		Maximum		407459
		Range		226092
		Interquartile Range		65638
		Skewness		.800 .398
		Kurtosis		.602 .778
		Post A	Mean	233706.17 10580.820
			95% Confidence Interval for Mean	Lower Bound Upper Bound
				212203.36 255208.98
			5% Trimmed Mean	229655.36
			Median	231192.00
			Variance	3918381076.323

	Std. Deviation	62596.973	
	Minimum	136725	
	Maximum	421872	
	Range	285147	
	Interquartile Range	81043	
	Skewness	.943	.398
	Kurtosis	1.509	.778
B	Mean	249421.57	9475.915
	95% Confidence Interval for Mean	Lower Bound Upper Bound	230164.20 268678.95
	5% Trimmed Mean	245897.85	
	Median	244941.00	
	Variance	3142753517.782	
	Std. Deviation	56060.267	
	Minimum	169383	
	Maximum	406211	
	Range	236828	
	Interquartile Range	70834	
	Skewness	.779	.398
	Kurtosis	.793	.778



Tests of Normality

		Kolmogorov-Smirnov ^a				Shapiro-Wilk		
		Hasil	Statistic	df	Sig.	Statistic	df	Sig.
Pre	A	.130	35		.144	.932	35	.033
	B	.122	35		.200*	.943	35	.068
Post	A	.107	35		.200*	.939	35	.053
	B	.104	35		.200*	.949	35	.108

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Dari hasil uji normalitas didapatkan hasil uji Kolmogorov-Smirnov dengan nilai $p > 0,05$, maka distribusi data normal, sehingga dilakukan uji parametrik Independent T Test.

T-Test

Group Statistics

		Hasil	N	Mean	Std. Deviation	Std. Error Mean
Pre	A	35	233706.17	62596.973	10580.820	
	B	35	249421.57	56060.267	9475.915	
Post	A	35	233706.17	62596.973	10580.820	
	B	35	249421.57	56060.267	9475.915	

Independent Samples Test									
Levene's Test for Equality of Variances				t-test for Equality of Means					
	F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
Pre	Equal variances assumed	.160	.691	-1.106	68	.272	-15715.400	14203.757	-44058.555 12627.755
	Equal variances not assumed			-1.106	67.189	.272	-15715.400	14203.757	-44064.749 12633.949
Post	Equal variances assumed	.160	.691	-1.106	68	.272	-15715.400	14203.757	-44058.555 12627.755
	Equal variances not assumed			-1.106	67.189	.272	-15715.400	14203.757	-44064.749 12633.949



Dari hasil uji Independent T Test, didapatkan :

Nilai $p > 0,05$ (0.272) untuk perbandingan krim A dan B (W0), sehingga disimpulkan tidak terdapat perbedaan kadar IL-12 yang bermakna setelah penggunaan krim A dan B sebelum 8 minggu.

Nilai $p > 0,05$ (0.272) untuk perbandingan krim A dan B (W8), sehingga disimpulkan tidak terdapat perbedaan kadar IL-12 yang bermakna setelah penggunaan krim A dan B setelah 8 minggu.

Perbandingan Penggunaan Krim A (W0) dan (W8)

Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
Pre Test	35	100.0%	0	0.0%	35	100.0%
Post Test	35	100.0%	0	0.0%	35	100.0%

Descriptives

			Statistic	Std. Error
			253736.83	9778.303
Pre Test	Mean		233864.93	
	95% Confidence Interval for Mean	Lower Bound	273608.73	
		Upper Bound	249607.16	
	5% Trimmed Mean		240603.00	
	Median			

	Variance	3346532022.08	
		7	
	Std. Deviation	57849.218	
	Minimum	172603	
	Maximum	432909	
	Range	260306	
	Interquartile Range	69098	
	Skewness	1.039	.398
	Kurtosis	1.502	.778
Post Test	Mean	257184.09	9335.636
	95% Confidence Interval for Mean	Lower Bound Upper Bound	238211.79 276156.38
	5% Trimmed Mean	253656.30	
	Median	246848.00	
	Variance	3050393428.61	
		0	
	Std. Deviation	55230.367	
	Minimum	181367	
	Maximum	407459	
	Range	226092	
	Interquartile Range	65638	
	Skewness	.800	.398
	Kurtosis	.602	.778

Tests of Normality

Kolmogorov-Smirnov ^a			Shapiro-Wilk			
	Statistic	df	Sig.	Statistic	df	Sig.
Pre Test	.130	35	.144	.932	35	.033
Post Test	.122	35	.200*	.943	35	.068

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Hasil uji normalitas menunjukkan nilai $p > 0,05$ pada uji Kolmogorov-Smirnov, maka distribusi data normal, sehingga dilakukan uji Paired Sample T Test.

T-Test

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Pre Test	253736.83	35	57849.218	9778.303
	Post Test	257184.09	35	55230.367	9335.636

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	Pre Test & Post Test	35	-.009	.961

Paired Samples Test									
			Paired Differences		95% Confidence Interval of the Difference				
	Mean	Std. Deviation	Std. Error Mean		Lower	Upper	t	df	
Pair 1 Pre Test - Post Test	-3447.257	80324.373	13577.297		-31039.645	24145.131	-.254	34	.801

Berdasarkan uji Paired Sample T Test, didapatkan nilai $p > 0,05$ (0.801), maka dapat disimpulkan tidak terdapat perbedaan kadar IL-12 yang bermakna sebelum (W0) dan sesudah (W8) penggunaan krim A.

Perbandingan Penggunaan Krim B (H0) dan (H5)

Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
Pre	35	100.0%	0	0.0%	35	100.0%
Post	35	100.0%	0	0.0%	35	100.0%

Descriptives

		Statistic		Std. Error
		Mean	95% Confidence Interval for	
Pre	233706.17		Lower Bound	10580.820
			212203.36	

	Mean	Upper Bound	255208.98	
	5% Trimmed Mean		229655.36	
	Median		231192.00	
	Variance		3918381076.323	
	Std. Deviation		62596.973	
	Minimum		136725	
	Maximum		421872	
	Range		285147	
	Interquartile Range		81043	
	Skewness		.943	.398
	Kurtosis		1.509	.778
Post	Mean		249421.57	9475.915
	95% Confidence Interval for	Lower Bound	230164.20	
	Mean	Upper Bound	268678.95	
	5% Trimmed Mean		245897.85	
	Median		244941.00	
	Variance		3142753517.782	
	Std. Deviation		56060.267	
	Minimum		169383	
	Maximum		406211	
	Range		236828	
	Interquartile Range		70834	
	Skewness		.779	.398
	Kurtosis		.793	.778

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Pre	.107	35	.200*	.939	35	.053
Post	.104	35	.200*	.949	35	.108

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Hasil uji normalitas menunjukkan nilai $p > 0,05$ pada uji Kolomogorov-Smirnof, maka distribusi data normal, sehingga dilakukan uji Paired Sample T test.

T-Test

Paired Samples Statistics


		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Pre	233706.17	35	62596.973	10580.820
	Post	249421.57	35	56060.267	9475.915


Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	Pre & Post	35	-.105	.550

Paired Samples Test										
			Paired Differences		95% Confidence Interval of the Difference					
	Mean	Std. Deviation	Std. Error Mean	Lower	Upper	t	df	Sig. (2-tailed)		
Pair 1	Pre - Post	-15715.400	88289.871	14923.712	-46044.032	14613.232	-1.053	34	.300	

Berdasarkan uji Paired Sample T Test, didapatkan nilai $p > 0,05$ (0,300), maka dapat disimpulkan tidak terdapat perbedaan kadar IL-12 sebelum (W0) dan sesudah (W8) penggunaan krim B.





Uji Kolerasi Antara IL12 dengan nilai Sebumeter

Uji kolerasi dilakukan dengan Uji Spearman, didapatkan beberapa data distribusi tidak normal $p>0.05$

			Sebumeter	Sebumeter
			IL12 W0 A	Dahi W0 A
Spearman's rho	IL12 W0 A	Correlation Coefficient	1.000	.177
		Sig. (2-tailed)	.	.308
		N	35	35
				.243
				.160
				35

Correlations

			Sebumeter	Sebumeter
			IL12 W8 A	Dahi W8 A
Spearman's rho	IL12 W8 A	Correlation Coefficient	1.000	.039
				-.242

	Sig. (2-tailed)	.	.825	.161
	N	35	35	35

Pada uji kolerasi Spearman antara kadar IL-12 dengan nilai sebumeter sesudah dan sebelum perlakuan pada dahi dan pipi didapatkan $p>0.05$. Tidak didapatkan adanya kolerasi antara kadar IL12 dan nilai sebumeter pada dahi dan pipi pada pemberian topical A.

Correlations

			IL12 W0	Sebumeter	Sebumeter
		B	Dahi W0 B	Pipi W0 B	
Spearman's rho	IL12 W0 B	Correlation	1.000	.095	.129
		Coefficient			
		Sig. (2-tailed)	.	.586	.460
		N	35	35	35

			IL12 W8	Sebumeter	Sebumeter
		B	Dahi W8 B	Pipi W8 B	
Spearman's rho	IL12 W8 B	Correlation	1.000	.016	-.022
		Coefficient			
		Sig. (2-tailed)	.	.929	.899
		N	35	35	35

Pada uji kolerasi Spearman antara kadar IL-12 dengan nilai sebumeter sesudah dan sebelum perlakuan pada dahi dan pipi didapatkan $p>0.05$. Tidak didapatkan adanya kolerasi antara kadar IL12 dan nilai sebumeter pada dahi dan pipi pada pemberian topical B.



